What is HC Wainwright's Forecast for Merus Q3 Earnings?

Key Points

• HC Wainwright estimates Merus will report a Q3 2025 earnings per share of ($1.31), maintaining a "Strong-Buy" rating on the stock.
• Merus' recent quarterly results show an earnings miss, reporting ($2.23) EPS against a consensus of ($1.17).
• Insider selling activity included COO Peter B. Silverman offloading 25,000 shares for a total of $1.5 million at an average price of $60.00.

Merus N.V. (NASDAQ:MRUS - Free Report) - Equities research analysts at HC Wainwright issued their Q3 2025 earnings per share estimates for shares of Merus in a report released on Wednesday, August 6th. HC Wainwright analyst A. Maldonado anticipates that the biotechnology company will earn ($1.31) per share for the quarter. HC Wainwright has a "Strong-Buy" rating on the stock. The consensus estimate for Merus' current full-year earnings is ($3.85) per share. HC Wainwright also issued estimates for Merus' Q4 2025 earnings at ($1.37) EPS, FY2025 earnings at ($6.27) EPS, FY2026 earnings at ($5.24) EPS, FY2027 earnings at ($4.19) EPS, FY2028 earnings at ($2.36) EPS and FY2029 earnings at $0.16 EPS.

Merus (NASDAQ:MRUS - Get Free Report) last issued its quarterly earnings data on Tuesday, August 5th. The biotechnology company reported ($2.23) EPS for the quarter, missing analysts' consensus estimates of ($1.17) by ($1.06). The company had revenue of $8.83 million for the quarter, compared to the consensus estimate of $9.77 million. Merus had a negative return on equity of 50.28% and a negative net margin of 685.64%.

Several other equities analysts have also issued reports on the company. William Blair reaffirmed an "outperform" rating on shares of Merus in a report on Monday, April 28th. BMO Capital Markets set a $110.00 target price on Merus and gave the company an "outperform" rating in a report on Friday, May 23rd. Wall Street Zen lowered Merus from a "hold" rating to a "sell" rating in a report on Sunday, July 20th. Needham & Company LLC reduced their target price on Merus from $97.00 to $96.00 and set a "buy" rating for the company in a report on Wednesday, August 6th. Finally, Wells Fargo & Company dropped their price objective on Merus from $91.00 to $89.00 and set an "overweight" rating on the stock in a research note on Thursday, May 8th. One research analyst has rated the stock with a sell rating, ten have assigned a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat, Merus currently has a consensus rating of "Moderate Buy" and an average price target of $88.50.

Merus Stock Performance

MRUS traded down $0.69 during midday trading on Monday, reaching $66.40. 151,116 shares of the company were exchanged, compared to its average volume of 879,089. The company's fifty day moving average price is $58.44 and its 200 day moving average price is $49.16. The company has a market cap of $5.02 billion, a price-to-earnings ratio of -12.00 and a beta of 1.09. Merus has a one year low of $33.19 and a one year high of $67.59.

Hedge Funds Weigh In On Merus

Hedge funds have recently added to or reduced their stakes in the company. Boxer Capital Management LLC bought a new stake in Merus in the 4th quarter worth approximately $79,895,000. Paradigm Biocapital Advisors LP grew its position in Merus by 99.4% in the 1st quarter. Paradigm Biocapital Advisors LP now owns 3,369,699 shares of the biotechnology company's stock worth $141,831,000 after purchasing an additional 1,679,777 shares during the period. Wellington Management Group LLP grew its position in Merus by 34.9% in the 1st quarter. Wellington Management Group LLP now owns 4,718,172 shares of the biotechnology company's stock worth $198,588,000 after purchasing an additional 1,220,519 shares during the period. Avoro Capital Advisors LLC grew its position in Merus by 56.8% in the 4th quarter. Avoro Capital Advisors LLC now owns 2,125,000 shares of the biotechnology company's stock worth $89,356,000 after purchasing an additional 770,000 shares during the period. Finally, Westfield Capital Management Co. LP grew its position in Merus by 36.0% in the 2nd quarter. Westfield Capital Management Co. LP now owns 2,042,388 shares of the biotechnology company's stock worth $107,430,000 after purchasing an additional 541,168 shares during the period. 96.14% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In related news, COO Peter B. Silverman sold 34,000 shares of the business's stock in a transaction that occurred on Friday, June 20th. The shares were sold at an average price of $52.76, for a total value of $1,793,840.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Insiders have sold 82,500 shares of company stock worth $4,586,340 in the last ninety days. 3.70% of the stock is currently owned by company insiders.

Merus Company Profile

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1.